BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/11/2022 12:11:23 AM | Browse: 435 | Download: 1015
 |
Received |
|
2021-03-22 14:24 |
|
Peer-Review Started |
|
2021-03-22 14:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-16 02:09 |
|
Revised |
|
2021-06-30 06:09 |
|
Second Decision |
|
2021-12-06 03:31 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-12-08 06:02 |
|
Articles in Press |
|
2021-12-08 06:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-12-31 04:21 |
|
Publish the Manuscript Online |
|
2022-01-11 00:11 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yi Luo, Fei Teng, Hong Fu and Guo-Shan Ding |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81702923 |
| National Natural Science Foundation of China |
81871262 |
|
| Corresponding Author |
Fei Teng, MD, PhD, Attending Doctor, Surgeon, Surgical Oncologist, Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, No. 415 Fengyang Road, Huangpu District, Shanghai 200003, China. tengfei@smmu.edu.cn |
| Key Words |
Hepatocellular carcinoma; Liver transplantation; Immunotherapy; Immune checkpoint inhibitors; Adoptive cell transfer; Immunosuppressant |
| Core Tip |
This review addresses revolutionized immunotherapy for hepatocellular carcinoma (HCC) in liver transplantation (LT), from downstaging or bridging management in the pretransplant setting to adjuvant or salvage strategy in the posttransplant setting. Considering that the benefit of the antitumor response outweighs the incremental risk of rejection, it is worthwhile to take immunotherapy into account as the salvage option when HCC recurs after LT. More prospective studies are required to provide direct evidence regarding immunosuppressant adjustment, biomarkers for response and the optimal selection of immunotherapy as well as patients. |
| Publish Date |
2022-01-11 00:11 |
| Citation |
Luo Y, Teng F, Fu H, Ding GS. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. World J Gastrointest Oncol 2022; 14(1): 163-180 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i1/163.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i1.163 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
